Drugs / Tarcocimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06270836 | May 2024 → Feb 2026 | diabetic retinopathy | Kodiak Sciences Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tarcocimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06270836 ↗ |
| Known as | OG-1950 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314617 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314617 ↗ |
| Route | Intravitreal | “Tarcocimab 5 mg via intravitreal injection” NCT06270836 ↗ |